DeepMed Research

Medical University of Vienna

🇦🇹Austria

Country: 🇦🇹Austria

Ownership: Private

Established: 1365-01-01

Employees: 1K

Market Cap: -

Website: http://www.meduniwien.ac.at

Clinical Trials

Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma

Phase 2

Completed

Conditions: Stage III Melanoma
Stage IV Melanoma

Interventions: Biological: Ofatumumab
Biological: Ofatumumab plus Dacarbazine

First Posted Date: 2011-06-20

Last Posted Date: 2015-10-06

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 10

Registration Number: NCT01376713

Locations: 🇦🇹
Rudolfstiftung, Vienna, Austria
🇦🇹
Medical University of Vienna, Vienna, Austria

Brain Natriuretic Peptide Effects on Appetite Regulating Hormones and Endothelial Derived Peptides

Not Applicable

Completed

Conditions: Healthy

Interventions: Drug: 0.9% NaCl
Drug: BNP

First Posted Date: 2011-06-17

Last Posted Date: 2017-04-06

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 10

Registration Number: NCT01375153

Locations: 🇦🇹
AKH, Medical University of Vienna, Vienna, Austria
🇦🇹
Medical University of Vienna, Vienna, Austria

Coupling of Neural Activity and Retinal Blood Flow in Diabetes

Terminated

Conditions: Diabetic Retinopathy

First Posted Date: 2011-06-17

Last Posted Date: 2020-02-20

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 1

Registration Number: NCT01375166

Locations: 🇦🇹
Department of Clinical Pharmacology, Vienna, Austria

Azithromycin Combination Therapy for the Treatment of Severe Malaria

Phase 2

Completed

Conditions: Falciparum Malaria

Interventions: Drug: Azithromycin + Artesunate
Drug: Artesunate

First Posted Date: 2011-06-15

Last Posted Date: 2013-08-23

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 75

Registration Number: NCT01374126

Locations: 🇧🇩
MARIB, Bandarban, Bangladesh

Drug Drug Interactions of Aspirin and P2Y12-inhibitors

Phase 4

Completed

Conditions: Myocardial Infarction
Drug Interaction Potentiation

Interventions: Drug: Placebo
Drug: Morphine

First Posted Date: 2011-06-08

Last Posted Date: 2017-03-27

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 95

Registration Number: NCT01369186

Locations: 🇦🇹
Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria

OMEGA-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Peripheral Arterial Disease

Phase 3

Completed

Conditions: Peripheral Arterial Disease

Interventions: Drug: Placebo
Drug: OMACOR

First Posted Date: 2011-06-06

Last Posted Date: 2014-08-26

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 71

Registration Number: NCT01367145

Locations: 🇦🇹
Medical University of Vienna, Department of Internal Medicine II, Division of Angiology, Vienna, Austria

Treatment of Dry Eye With Supplements

Not Applicable

Withdrawn

Conditions: Dry Eye Syndromes

First Posted Date: 2011-06-02

Last Posted Date: 2015-04-15

Lead Sponsor: Medical University of Vienna

Registration Number: NCT01364311

Locations: 🇦🇹
Department of Clinical Pharmacology, Medical University Vienna, Vienna, Austria

Value of Von Willebrand Factor in Portal Hypertension

Conditions: Liver Cirrhosis
Portal Hypertension

First Posted Date: 2011-05-23

Last Posted Date: 2015-09-25

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 300

Registration Number: NCT01358123

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria

Antiangiogenic Therapy for Children with Recurrent Medulloblastoma, Ependymoma and ATRT

Phase 2

Recruiting

Conditions: Medulloblastoma Recurrent
ATRT Recurrent
Ependymoma Recurrent

First Posted Date: 2011-05-19

Last Posted Date: 2024-10-21

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 100

Registration Number: NCT01356290

Locations: 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States

and more 19 locations

Immune Response of Individuals Vaccinated With Hypoallergenic Derivatives of the Major Birch Pollen Allergen, Bet v 1

Phase 1

Conditions: Allergy

Interventions: Biological: Bet v 1aF1-Alum + Bet v 1aF2-Alum
Biological: Alum-Placebo

First Posted Date: 2011-05-16

Last Posted Date: 2011-05-16

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 20

Registration Number: NCT01353924

Locations: 🇦🇹
Allergiezentrum Wien West, Vienna, Austria
🇦🇹
Medical University of Vienna, Department of Pathophysiology, Vienna, Austria

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy